Dr. Rasha Omar Elsaka

assistant

 

Education
2009 - 2015  Doctor Degree of Clinical Oncology, University of Alexandria, Egypt
2005 - 2008  Master Degree of Radiation Oncology, University of Alexandria, Egypt 
1997-2003  Medical education at Faculty of Medicine, University of Alexandria, Egypt. Bachelor degree of Medicine and Surgery (MBBCh) in 2003 

 

Work & Experience
  • Currently: Lecturer at Clinical Oncology Department, Faculty of Medicine, Alexandria University, Egypt
  • Research Scholar in Radiation Oncology Dept. Moffitt Cancer Center, Tampa, FL, USA
  • Research Fellow in Radiation Oncology Dept. Henry Ford Hospital, Detroit, MI, US
  • Residency at Clinical Oncology Department, Alexandria Main University Hospital, Egypt.

 

Research
  1. Co-Investigator in Clinical Trial CRAD001Y2301: A Randomized Double-Blinded, Placebo-Controlled Study of Everolimus in Combination with Exemestane in the Treatment of Postmenopausal Women with Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer who are refractory to Letrezole or Anastrazole, Novartis. Clinical research center, University of Alexandria.
  2. Sub-investigator in Clinical Study Protocol M10-897: A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy Versus Placebo and Whole Brain Radiation Therapy in Subjects with Brain Metastases from Non-Small Cell Lung Cancer. Clinical research center, University of Alexandria
  3. Sub-investigator in Clinical Study Protocol 1200.131 Study (LUX-Head & Neck 2): A randomized, double-blind, placebo-controlled, phase III study to evaluate the efficacy & safety of afatinib (BIBW 2992) as adjuvant therapy after chemo-radiotherapy in primary unresected patients with stage III, IVa, or IVb loco-regionally advanced head and neck squamous cell carcinoma. Clinical research center, University of Alexandria (Ongoing)
  4. Sub-investigator in Clinical Study Protocol BI 1200.217: An open label, single-arm phase IV study to assess the efficacy and safety of afatinib as second-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harbouring an EGFR mutation (Del19 or L858R) who have failed first-line treatment with platinum-based chemotherapy. Clinical research center, University of Alexandria (Ongoing)

 

Publications
  • Scalp cooler efficacy to reduce anthracycline-induced alopecia and its Quality of Life impact in breast cancer patients. R. O. El-saka, G. El-Husseiny, Y. Rostom, A. Salama; Faculty of Medicine, Alexandria, Egypt Abstract number e13539, 2009 Annual Meeting of ASCO (the American Society of Clinical Oncology).
  • Establishment of Benchmark CBCT/ CT Deformable Image Registration in Radiotherapy of Prostate cancer. S Kumar, S Siddiqui, R Yechieli, J Robbins, D Pradhan, M M Shah, R El Saka, M Elshaikh, J Kim, Henry Ford Health System, Detroit, MI, USA. Abstract in the 54th ASTRO annual meeting in 2012. International Journal of Radiation Oncology * Biology * Physics Vol. 84, Issue 3, Supplement, Page S393
  • Outcomes for hormone naiive patients who achieved undetectable PSA after salvage radiation treatment post-prostatectomy. J Robbins, R Elsaka, G Jacobson, B Movsas, M Elshaikh. Henry Ford Health System, Detroit, MI, USA. abstract in the 54th ASTRO annual meeting in 2012. International Journal of Radiation Oncology * Biology * Physics Vol. 84, Issue 3, Supplement, Page S814
  • 3DCRT for posterior fossa: Sparing of surrounding organs at risk. A Helal, M Farouk, R Elsaka, S Fadel. AJM. Article in press; accepted 16 May 2013. published online 26 June 2013.
  • A novel gene signature to predict distant metastasis in stage I lung cancer patient following local therapy with surgery or stereotactic body radiation therapy (SBRT). S Kim, D Chen, A F Al-Rashdan, R Elsaka, L Robinson, E B. Haura, J Torres-Roca, T J. Dilling, C Stevens. Abstract in the 50th ASCO annual meeting in 2014. Abstract No 7538